PULMONARY ARTERIAL HYPERTENSION PAH

This study compares starting with two oral medications (tadalafil and ambrisentan) versus just one in people newly diagnosed with pulmonary arterial hypertension who also have at least two heart-related conditions. The goal is to see which approach better lowers risk and improves…

This study tests an experimental oral drug, ROC-101, in 40 adults with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (ILD-PH). Participants take the drug alongside their usual care for 24 weeks, with a long-term follow-up. The…

This study tests an experimental drug called IMC-003 in people with pulmonary arterial hypertension (PAH), a serious condition where high blood pressure damages the lungs and heart. The trial involves 120 adults who are already on standard treatment. Researchers want to see if th…

This study tests whether sotatercept, a new drug that targets the root cause of blood vessel scarring in the lungs, can improve right heart function in people with pulmonary arterial hypertension (PAH). About 20 adults with moderate to severe PAH will receive injections every thr…

This study tests an experimental drug called REGN13335 for people with pulmonary arterial hypertension (PAH), a condition that makes it hard for the heart to pump blood to the lungs. About 99 adults with mild to moderate symptoms who are already on standard PAH medications will r…

This study tests whether a home rehabilitation program can reduce the number of heartbeats needed during a 6-minute walk for people with pulmonary arterial hypertension (PAH). Researchers will also measure changes in walking distance and quality of life. The program involves 55 a…

This early-stage study tests whether artesunate, a malaria drug, is safe for people with pulmonary arterial hypertension (PAH). Fifteen adults with PAH will take daily oral artesunate for 20 weeks. The main goal is to check for side effects, not to treat the disease.

This study looks at whether guidance from a pharmacist can help people with pulmonary arterial hypertension (PAH) stick to their inhaled medication, iloprost. PAH is a serious lung condition that makes it hard to breathe and can lead to heart failure. The study will enroll 72 adu…

This study looks at what happens when people with pulmonary arterial hypertension (PAH) switch from one medication (ambrisentan) to another (bosentan). Researchers will track 121 adults over 3-6 months to see if their risk scores, symptoms, and lab results change. The goal is to …

This study is creating and testing a questionnaire to see how much people with pulmonary arterial hypertension (PAH) know about their disease. Researchers will check if the questions make sense to patients and experts, and if the tool gives reliable results. Up to 200 adults with…

This study aims to understand why diagnosing pulmonary arterial hypertension (PAH), a rare and serious lung disease, often takes a long time. Researchers will review medical records from 139 adults in Brazil to track how long symptoms go unnoticed and how many doctors are seen be…

This early-stage study tests a new drug called ZMA001 in 96 healthy adults aged 18 to 60. The goal is to check if it is safe and how the body processes it before testing it in people with a serious lung condition called pulmonary arterial hypertension (PAH). Participants receive …